168 related articles for article (PubMed ID: 29988818)
21. Cationic nanoemulsions as nucleic acids delivery systems.
Teixeira HF; Bruxel F; Fraga M; Schuh RS; Zorzi GK; Matte U; Fattal E
Int J Pharm; 2017 Dec; 534(1-2):356-367. PubMed ID: 29038065
[TBL] [Abstract][Full Text] [Related]
22. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits.
Chetoni P; Burgalassi S; Monti D; Tampucci S; Tullio V; Cuffini AM; Muntoni E; Spagnolo R; Zara GP; Cavalli R
Eur J Pharm Biopharm; 2016 Dec; 109():214-223. PubMed ID: 27789355
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in Topical Ocular Drug Delivery.
Yellepeddi VK; Palakurthi S
J Ocul Pharmacol Ther; 2016 Mar; 32(2):67-82. PubMed ID: 26666398
[TBL] [Abstract][Full Text] [Related]
24. Nanostructured lipid carriers system: recent advances in drug delivery.
Iqbal MA; Md S; Sahni JK; Baboota S; Dang S; Ali J
J Drug Target; 2012 Dec; 20(10):813-30. PubMed ID: 22931500
[TBL] [Abstract][Full Text] [Related]
25. Topical delivery of ocular therapeutics: carrier systems and physical methods.
Souza JG; Dias K; Pereira TA; Bernardi DS; Lopez RF
J Pharm Pharmacol; 2014 Apr; 66(4):507-30. PubMed ID: 24635555
[TBL] [Abstract][Full Text] [Related]
26. Drug delivery to the eye: what benefits do nanocarriers offer?
Joseph RR; Venkatraman SS
Nanomedicine (Lond); 2017 Mar; 12(6):683-702. PubMed ID: 28186436
[TBL] [Abstract][Full Text] [Related]
27. Advanced drug and gene delivery systems based on functional biodegradable polycarbonates and copolymers.
Chen W; Meng F; Cheng R; Deng C; Feijen J; Zhong Z
J Control Release; 2014 Sep; 190():398-414. PubMed ID: 24858708
[TBL] [Abstract][Full Text] [Related]
28. Light activated liposomes: Functionality and prospects in ocular drug delivery.
Lajunen T; Nurmi R; Kontturi L; Viitala L; Yliperttula M; Murtomäki L; Urtti A
J Control Release; 2016 Dec; 244(Pt B):157-166. PubMed ID: 27565215
[TBL] [Abstract][Full Text] [Related]
29. Development of ocular drug delivery systems using molecularly imprinted soft contact lenses.
Tashakori-Sabzevar F; Mohajeri SA
Drug Dev Ind Pharm; 2015 May; 41(5):703-13. PubMed ID: 25113431
[TBL] [Abstract][Full Text] [Related]
30. Regulatory issues in cell-based therapy for clinical purposes.
Casaroli-Marano RP; Tabera J; Vilarrodona A; Trias E
Dev Ophthalmol; 2014; 53():189-200. PubMed ID: 24732772
[TBL] [Abstract][Full Text] [Related]
31. Engineered nanoparticles as precise drug delivery systems.
Yih TC; Al-Fandi M
J Cell Biochem; 2006 Apr; 97(6):1184-90. PubMed ID: 16440317
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment.
Ashfaq UA; Riaz M; Yasmeen E; Yousaf MZ
Crit Rev Ther Drug Carrier Syst; 2017; 34(4):317-353. PubMed ID: 29199588
[TBL] [Abstract][Full Text] [Related]
33. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part II - Ocular drug-loaded lipid nanoparticles.
Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
Eur J Pharm Biopharm; 2017 Jan; 110():58-69. PubMed ID: 27789359
[TBL] [Abstract][Full Text] [Related]
34. Challenges and solutions in topical ocular drug-delivery systems.
Ali M; Byrne ME
Expert Rev Clin Pharmacol; 2008 Jan; 1(1):145-61. PubMed ID: 24410518
[TBL] [Abstract][Full Text] [Related]
35. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
36. [Regulatory Science in Practice (Pharmaceuticals and Medical Devices Agency)].
Hojo T
Yakugaku Zasshi; 2017; 137(4):439-442. PubMed ID: 28381721
[TBL] [Abstract][Full Text] [Related]
37. Nanotechnology in ocular drug delivery.
Sahoo SK; Dilnawaz F; Krishnakumar S
Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912
[TBL] [Abstract][Full Text] [Related]
38. Microchips and controlled-release drug reservoirs.
Staples M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(4):400-17. PubMed ID: 20564466
[TBL] [Abstract][Full Text] [Related]
39. Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.
Bravo-Osuna I; Andrés-Guerrero V; Pastoriza Abal P; Molina-Martínez IT; Herrero-Vanrell R
Drug Deliv Transl Res; 2016 Dec; 6(6):686-707. PubMed ID: 27766598
[TBL] [Abstract][Full Text] [Related]
40. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
Bisht R; Jaiswal JK; Rupenthal ID
Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
